Humacyte
Morrisville
About Humacyte
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $955.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:HUMA
- Website: humacyte.com
- Phone: 9193139634
Industries & Categories
Biotechnology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/humacyte-43687 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.